industries, with the Palestinian companies owning 55% and 30% market share of the private and public sectors respectively, and high potential of growth even more, in a market estimated at around USD 100 million. All these companies mostly reproduce generics that are seen as commodities rather than differentiated, and highly depend on preferred agreements with pharmacies, doctors, hospitals and medical centers to serve both as their marketing and distribution channels. All operating firms in the industry
Words: 1927 - Pages: 8
are to result from it: • The new entity/firm will be the world’s fifth largest specialty-generic pharma company with sales of US$ 4.2 billionfor CY 2013. • The entity will have a presence in 55 countries and be supported by 40 manufacturing facilities worldwide, with a highly complementary portfolio of products for both acute and chronic treatments. • In the U.S., the merged entity will be No.1 in the generic dermatology market and No. 3 in the branded dermatology market. It will also become the
Words: 738 - Pages: 3
Introduction An investigation into a pharmaceutical company’s supposed intentions to curtail generic competition regarding an antidepressant drug, which is the company’s best brand name seller, has brought about a few questions as to why the company would do this to consumers. Prescription medication is expensive enough without pharmaceutical companies hindering the market entry of its generic counterparts. Generic medication gives consumers a choice to spend more or to spend less for their health
Words: 2007 - Pages: 9
since insurance and social security do not cover all the costs, the elderly are paying out of pocket for their medications. Employees in the medical field should prescribe drugs that treat multiple symptoms, suggest substituting brand names for generic names, and navigate patients to cost effective programs. Healthcare administrators need to create a policy for medical staff that will require them to monitor and provide more financially suitable healthcare options for elderly consumers in addition
Words: 1298 - Pages: 6
stakeholders are first and foremost patients. They receive free samples. The argument is that if physians are pampered by detailers, then they would prescribe more non generic drugs. I don’t agree with that assumption. The public must understand that once the patent runs out on a drug, then it can be produced by competitors in generic form. Physicians would have no incentive to write one RX over another. The Issue is that Detailers have resources to “pamper” physicians and influence their decision
Words: 387 - Pages: 2
pharmaceutical company in Bangladesh .The Company was founded in 1958 by Samson H. Chowdhury along with three of his friends as a private firm. It was converted into a public limited company in 1991. It is engaged in the manufacturing of branded generic pharmaceutical products and also other ethical drugs and medicines. The company formulation facilities include Pabna Unit, Dhaka Unit, Pesticide Unit, Cephalosporin Unit and Animal Health Unit. Square Pharmaceuticals Limited has extended its range
Words: 4423 - Pages: 18
Merck, the FDA, and the Vioxx Recall In 1999 the Food and Drug Administration (FDA) had approved Vioxx, what would become Merck’s “blockbuster” drug. Although the FDA had approved the drug there was uncertainty of the safety of drug. Vioxx was approved to treat a variety of conditions, such as osteoarthritis and acute pain, but there was also a chance that it would increase cardiovascular problems. What I found most interesting about this case was the changes in how drugs are brought to consumers
Words: 548 - Pages: 3
Prices soar on generics Some low-cost generic drugs that have helped restrain health care costs for decades are seeing unexpected price spikes of up to 8,000 per cent, prompting a backlash from patients, pharmacists and now Washington lawmakers. A Senate panel met Thursday to scrutinize the recent, unexpected trend among generic medicines, which usually cost 30 to 80 per cent less than their branded counterparts. Experts said there are multiple, often unrelated, forces behind the price hikes
Words: 350 - Pages: 2
companies are classified according to their level of investment in Research and Development (R&D): the “Principal Companies” are the companies which have large investments in R&D to produce patented drugs, whereas “Generic Companies” produce offpatent drugs. Generic drugs (Generics or Branded Pharmaceuticals) are defined by Brems et al. (2011) as off-patent drugs which are not offered by the original manufacturer (Principal Companies) and under different brand names, and they represent a substantial
Words: 4085 - Pages: 17
expensive clinical studies and the barriers to market access. Unlike chemical-based prescription drugs, biologic drugs are derived from living cells. They are used to treat cancers, immunological diseases and other chronic illnesses. Biosimilars are generic versions of biological drugs that are similar to innovative biological drugs. The Patient Protection and Affordable Care Act (PPACA) became law in 2010. Section XII of the law allows an abbreviated approval pathway for biosimilars. FDA is currently
Words: 1491 - Pages: 6
